Edelman Joseph's Form 4 filing
Adma Biologics, Inc. (ADMA) · filed Aug 19, 2021
- Accession no.
- 0001062993-21-007800
- Filed
- Aug 19, 2021, 7:58 PM ET
- Trade date
- Aug 17-19, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions. Open-market sales total $2.33M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Edelman JosephCIK 0001164426 | 10% Owner |
| Perceptive Advisors LLCCIK 0001224962 | 10% Owner |
| Perceptive Life Sciences Master Fund LtdCIK 0001249675 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 17, 2021 | Common Stock | SSaleDisposed | −879,092 | $1.35F1 | −$1,186,774.2 | 15,705,710 | Indirect | |
| Aug 18, 2021 | Common Stock | SSaleDisposed | −552,380 | $1.29F2 | −$712,570.2 | 15,153,330 | Indirect | |
| Aug 19, 2021 | Common Stock | SSaleDisposed | −350,352 | $1.24F3 | −$434,436.48 | 14,802,978 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.33 to $1.41, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within such range.
Referenced by the price of 1 transaction in Table I.
- F2
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.26 to $1.33, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within such range.
Referenced by the price of 1 transaction in Table I.
- F3
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.22 to $1.27, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within such range.
Referenced by the price of 1 transaction in Table I.